Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use

M. Hodolic, WY. Wu, Z. Zhao, F. Yu, I. Virgolini, F. Wang

. 2021 ; 48 (4) : 1229-1234. [pub] 20201002

Language English Country Germany

Document type Clinical Trial, Journal Article

Persistent link   https://www.medvik.cz/link/bmc21018908

INTRODUCTION: Over the last decades, multiple peptide receptors were recognized as potential diagnostic and therapeutic targets in nuclear medicine. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. High neurotensin receptor expression has been observed in pancreatic ductal adenocarcinoma as well as various malignancies. Until now, 68Ga-labelled NT ligand was successfully applied in in vitro as well as in animal model. Our study is the first in-human study on safety and tolerability of 68Ga-NT-20.3. METHODS: Subjects were intravenously injected with 2.5 MBq of 68Ga-DOTA-NT-20.3 per kilogramme of body weight, and series of PET images were acquired at 5-25 min, 25-45 min, 45-65 min, and 65-85 min after 68Ga-NT-20.3 injection. Vital parameters are as follows: systolic and diastolic blood pressure (mmHg), heart rate (heart beat/min), respiratory rate (number of breaths/min), ECG, and body temperature (°C) were checked before, immediately after, and 3 h after 68Ga-NT-20.3 injection. The organ-absorbed doses were calculated for the self-dose and cross-dose from each organ region using the OLINDA/EXM version 2.1 software. RESULTS AND CONCLUSION: The results from this small trial demonstrate that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018908
003      
CZ-PrNML
005      
20210830100459.0
007      
ta
008      
210728s2021 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00259-020-05045-w $2 doi
035    __
$a (PubMed)33006657
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Hodolic, Marina $u Nuclear Medicine Research Department, IASON, Graz, Austria. marina.hodolic@gmail.com $u Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacký University Olomouc, Olomouc, Czech Republic. marina.hodolic@gmail.com
245    10
$a Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use / $c M. Hodolic, WY. Wu, Z. Zhao, F. Yu, I. Virgolini, F. Wang
520    9_
$a INTRODUCTION: Over the last decades, multiple peptide receptors were recognized as potential diagnostic and therapeutic targets in nuclear medicine. 68Ga-NT-20.3 radiopharmaceutical has been developed for diagnosis of neurotensin receptors. High neurotensin receptor expression has been observed in pancreatic ductal adenocarcinoma as well as various malignancies. Until now, 68Ga-labelled NT ligand was successfully applied in in vitro as well as in animal model. Our study is the first in-human study on safety and tolerability of 68Ga-NT-20.3. METHODS: Subjects were intravenously injected with 2.5 MBq of 68Ga-DOTA-NT-20.3 per kilogramme of body weight, and series of PET images were acquired at 5-25 min, 25-45 min, 45-65 min, and 65-85 min after 68Ga-NT-20.3 injection. Vital parameters are as follows: systolic and diastolic blood pressure (mmHg), heart rate (heart beat/min), respiratory rate (number of breaths/min), ECG, and body temperature (°C) were checked before, immediately after, and 3 h after 68Ga-NT-20.3 injection. The organ-absorbed doses were calculated for the self-dose and cross-dose from each organ region using the OLINDA/EXM version 2.1 software. RESULTS AND CONCLUSION: The results from this small trial demonstrate that PET radiopharmaceutical 68Ga-NT-20.3 is safe and well tolerated.
650    _2
$a zvířata $7 D000818
650    12
$a duktální karcinom slinivky břišní $x diagnostické zobrazování $7 D021441
650    _2
$a radioizotopy galia $7 D005710
650    _2
$a lidé $7 D006801
650    12
$a nádory slinivky břišní $x diagnostické zobrazování $7 D010190
650    _2
$a radiofarmaka $7 D019275
650    _2
$a receptory neurotensinu $7 D018028
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wu, Wen-Yu $u Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
700    1_
$a Zhao, Zhenyu $u Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
700    1_
$a Yu, Fei $u Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
700    1_
$a Virgolini, Irene $u Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
700    1_
$a Wang, Feng $u Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
773    0_
$w MED00007222 $t European journal of nuclear medicine and molecular imaging $x 1619-7089 $g Roč. 48, č. 4 (2021), s. 1229-1234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33006657 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100500 $b ABA008
999    __
$a ok $b bmc $g 1689866 $s 1139354
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 48 $c 4 $d 1229-1234 $e 20201002 $i 1619-7089 $m European journal of nuclear medicine and molecular imaging $n Eur J Nucl Med Mol Imaging $x MED00007222
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Archiving options